Latest Breaking News On - Abbie celniker - Page 3 : comparemela.com
Abata Opens With Plans to Develop T-cell Therapies for Progressive MS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Flare Therapeutics launches to target transcription factors
acs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acs.org Daily Mail and Mail on Sunday newspapers.
Flare Therapeutics, a Cambridge, Mass. – based biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, raised $82m in Series A financing.
The round was led by Third Rock Ventures with participation from Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.
The company intends to use the funds for further advancement of its lead program in precision oncology toward the clinic proprietary assays to discover small molecules that target transcription factors at switch sites.
Led by Abbie Celniker, PhD, interim chief executive officer, Flare is a biotechnology company with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, the team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address m
Published May 13, 2021 Dollar Photo Club
The instructions for making a human are long and complicated. They involve over 3 billion sets of microscopic letters, so tightly coiled that, if unwound, they would be taller than the average person.
The daunting task of reading these instructions involves a type of protein called transcription factors. But, while integral to life, these proteins can also cause disease when they mutate or malfunction.
For drug developers, transcription factors are an attractive target. Every biotech company that I ve been a part of has been interested in at least one or two, said Abbie Celniker, a well-known industry veteran and a partner at the healthcare investment firm Third Rock Ventures. That s been true since the early 1990s, according to Celniker, who s worked at high-profile companies including Novartis, Millennium Pharmaceuticals and Genentech.